IP Library › Granted Patent US 12,246,095
Granted Patent B2
US 12,246,095 · App. 18/369,754 · Granted Mar 11, 2025

Oral dosage forms comprising a hops extract

Inventors: John Ronald Ingram (Auckland, NZ); Edward George Walker (Auckland, NZ)
Assignee: The New Zealand Institute for Plant and Food Research Limited
A61K9/4875A61K9/0053A61K9/4816A61K31/122A61K36/185
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,246,095
App. No.
18/369,754
Granted
Mar 11, 2025
Kind
B2
Abstract

This invention provides novel oral dosage forms comprising a hops extract. The oral dosage forms are capable of activating bitter taste receptors expressed in the gastrointestinal tract. The applications include but are not limited to the use of the oral dosage forms for reducing energy intake and/or appetite in a subject.

Claims (38)

1. A delayed release oral dosage form comprising a hops extract having an acid component, wherein at least 80% of the acid component of the hops extract is not isomerised.

2. The oral dosage form according to claim 1 , wherein at least 90% of the acid component of the hops extract is not isomerised.

3. The oral dosage form according to claim 1 , wherein the hops extract comprises from about 25% to about 100% w/w alpha-acids.

4. The oral dosage form according to claim 1 , wherein the hops extract comprises from about 40% to about 55% w/w alpha-acids.

5. The oral dosage form according to claim 1 , wherein the hops extract comprises greater than 50% w/w alpha-acids.

6. The oral dosage form according to claim 1 , wherein the hops extract comprises from about 10% to about 50% w/w beta-acids.

7. The oral dosage form according to claim 1 , wherein the alpha acid component of the hops extract comprises from about 10% to about 45% w/w cohumulone.

8. The oral dosage form according to claim 1 , wherein the alpha acid component of the hops extract comprises from about 15% to about 25% 15-25% cohumulone.

9. The oral dosage form according to claim 1 , wherein the alpha acid component of the hops extract comprises about 20% w/w cohumulone.

10. The oral dosage form according to claim 1 , comprising from about 5 to about 1000 mg of hops extract.

11. The oral dosage form according to claim 1 , comprising about 50 mg of hops extract.

12. The oral dosage form according to claim 1 , comprising about 100 mg of hops extract.

13. The oral dosage form according to claim 1 , wherein the hops extract is from a cultivar with a high alpha acid or high cohumulone content.

14. The oral dosage form according to claim 1 , wherein the hops extract is a supercritical CO 2 extract.

15. The oral dosage form according to claim 1 , wherein the oral dosage form further comprises an edible oil.

16. The oral dosage form according to claim 15 , wherein the edible oil is selected from the group consisting of: canola, flaxseed, corn, soybean, mineral, safflower, sesame, coconut, avocado, peanut oil, olive oil, and liquid paraffin.

17. The oral dosage form according to claim 15 , wherein the ratio of edible oil to hops extract is from 10:1 to 1:10.

18. The oral dosage form according to claim 15 , wherein the ratio of edible oil to hops extract is about 1:1 to about 4:1.

19. The oral dosage form according to claim 1 , wherein the oral dosage form further comprises a preservative.

20. The oral dosage form according to claim 19 , wherein the preservative is selected from the group consisting of: ethyl p-hydroxybenzoate, n-propyl p-hydroxybenzoate, an antioxidant, rosemary oil, Vitamin E, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate (PG), and tert-Butylhydroquinone (TBHQ), and mixtures thereof.

21. The oral dosage form according to claim 1 , wherein the oral dosage form further comprises a viscosity modifier.

22. The oral dosage form according to claim 1 , which is in a form selected from the group consisting of: tablets, capsules, pills, pellets, capsules containing liquids, troches, dragees, pastilles, lozenges, multilayer forms, and coated forms.

23. The oral dosage form according to claim 1 , which is in the form of a capsule.

24. The oral dosage form according to claim 1 , wherein the contents of the oral dosage form has a viscosity between 250 cP and 8000 cP.

25. A method of

(a) reducing appetite

(b) increasing satiety hormones

(c) weight management

(d) appetite control

(e) decreasing food intake

(f) inducing satiety and/or

(g) treating obesity

comprising administering an oral dosage form according to claim 1 to a subject.

26. The method according to claim 25 , wherein the oral dosage form is administered to the subject at least one hour before meal time, at least one hour before an eating occasion, or during a period of fasting.

27. The method according to claim 25 , wherein the subject is following an intermittent fasting protocol.

28. A method of reducing energy intake by a subject comprising administering an agent capable of binding TAS2R1, TAS2R14 and TAS2R40 in the gastrointestinal tract of the subject.

29. A method according to claim 28 , wherein the agent is administered as a delayed release oral dosage form which comprises or consists essentially of cohumulone.

30. A method according to claim 28 , wherein the agent is administered as a delayed release oral dosage form comprising a hops extract having an acid component, wherein the acid component of the hops extract is not isomerised.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jun 24, 2026
From: THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED; NEW ZEALAND INSTITUTE FOR BIOECONOMY SCIENCE LIMITED
To: NEW ZEALAND INSTITUTE FOR BIOECONOMY SCIENCE LIMITED
Reel/Frame 075069/0306 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2023
From: INGRAM, JOHN RONALD; WALKER, EDWARD GEORGE
To: THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED
Reel/Frame 064977/0617 →
Priority Claims (1)
AU 2018900489 · Feb 16, 2018 · national
Continuity (2)
Continuation 16970218
Related Publication 20240000716A1 · Jan 4, 2024
References Cited (69)
US 8980953B2 · Taniguchi et al. · 2015 [cited by applicant]
US 9861611B2 · Bromley · 2018 [cited by applicant]
US 20020086070A1 · Kuhrts · 2002 [cited by applicant]
US 20050101581A1 · Reading et al. · 2005 [cited by applicant]
US 20060013870A1 · Kuhrts · 2006 [cited by applicant]
US 20080248145A1 · Heuer · 2008 [cited by examiner]
US 20090087512A1 · Tripp et al. · 2009 [cited by applicant]
US 20090186142A1 · Tatewaki et al. · 2009 [cited by applicant]
US 20130316068A1 · Taniguchi et al. · 2013 [cited by applicant]
US 20150197472A1 · Dahlberg · 2015 [cited by applicant]
US 20160081975A1 · Bromley · 2016 [cited by applicant]
US 20210077412A1 · Ingram et al. · 2021 [cited by applicant]
CN 1814094A · 2006 [cited by applicant]
DE 10255481A1 · 2004 [cited by applicant]
EP 677289A2 · 1995 [cited by examiner]
GB 510931 · 1939 [cited by applicant]
NZ 527902B · 2005 [cited by applicant]
WO WO1999020289A1 · 1999 [cited by applicant]
WO WO2006138253A1 · 2006 [cited by applicant]
WO WO2007041499A2 · 2007 [cited by applicant]
WO WO2008113177A1 · 2008 [cited by applicant]
WO WO2010068693A1 · 2010 [cited by applicant]
WO WO2011151285A1 · 2011 [cited by applicant]
WO WO2012094636A2 · 2012 [cited by applicant]
WO WO2016178589A1 · 2016 [cited by applicant]
Andreozzi et al. (2015) “The Bitter Taste Receptor Agonist Quinine Reduces Calorie Intake and Increases the Postprandial Release of Cholecystokinin in Healthy Subjects,” J Neurogastroenterol Motil 21(4): 511-519. [cited by applicant]
Avau et al. (2015) “Targeting extra-oral bitter taste receptors modulates gastrointestinal motility with effects on satiation,” Scientific reports vol. 5, Article No. 15985: 12 pages. [cited by applicant]
Avau et al. (2016) “The bitter truth about bitter taste receptors: beyond sensing bitter in the oral cavity,” Acta Physiol 216, pp. 407-420. [cited by applicant]
Beatson et al. (1994) “Regional trial evaluation and cultivar selection of triploid hop hybrids”, New Zealand Jouranl of Crop and Horticultural Science 22(1), pp. 1-6. [cited by applicant]
Bowden (2016) available online at http://www.listener.co.nz/lifestyle/nutrition/plant-extract-weight-loss, 1 page. [cited by applicant]
Broughton (2016) “Plant extract hailed as key to fighting fat epidemic,” available online at https://www.stuff.co.nz/life-style/well-good/teach-me/80711494/kiwi-plant-extract-hailed-as-key-to-fighting-fat-epidemic, 7 pa… [cited by applicant]
Chen et al. (2006) “Bitter stimuli induce Ca2+ signaling and CCK release in enteroendocrine STC-1 cells: role of L-type voltage-sensitive Ca2+ channels,” Am J Physiol Cell Physiol, 291(4): C726-C739. [cited by applicant]
Clinical trial “The Effect of Bitter, Umami and Sweet Tastants on Food Intake,” This study has been completed. Sponsor: Maastricht University Medical Center. Information provided by (Responsible Party): Maastricht Unive… [cited by applicant]
Daniells (2012) “Hop extract shows weight management potential,” available online at https://www.nutraingredients-usa.com/Article/2012/09/26/Hop-extract-shows-weight-management-potential, 2 pages. [cited by applicant]
Deloose et al. (2013) “In Man Intragastric Administration of the Bitter Compound Denatonium Benzoate Decreases Hunger and the Occurrence of Gastric Phase III in the Fasting State,” Gastroenterology, 144(5) Supplement 1:… [cited by applicant]
Depoortere (2014) “Taste receptors of the gut: emerging roles in health and disease,” Gut 63(1): 179-190. doi: 10.1136/gutjnl-2013-305112. Epub Oct. 16, 2013. PMID: 24131638. [cited by applicant]
Dotson et al. (2008) “Bitter Taste Receptors Influence Glucose Homeostasis,” PLoS One 3(12): 10 pages. [cited by applicant]
Everard et al. (2012) “Tetrahydro iso-alpha acids from hops improve glucose homeostasis and reduce body weight gain and metabolic endotoxemia in high-fat diet-fed mice,” PLoS One 7(3): 8 pages. [cited by applicant]
Extended European Search Report and Opinion mailed Nov. 4, 2021 in corresponding European Patent Application No. 18906321.7. [cited by applicant]
Green Flash Brewing Company (2017) “Green Flash Pacific Gem Single Hop Pale Ale,” available online at https://www.ratebeer.com/beer/greenflashpacificgemsinglehoppaleale/363325, 4 pages. [cited by applicant]
Hautke et al. (1967) “The influence of environmental conditions on the proportions of cohumulone ashumulone and humulone in Hop a acids,” Journal of the Institute of brewing vol. 73: 51-59. [cited by applicant]
Ingram et al. (2012), “Foods for appetite control: Developing plant-based functional foods targeting satiety,” Obesity Research & Clinical Practice 6(S1): 20 (abstract only). [cited by applicant]
Ingram et al. (2016) “A proprietary plant-based, functional ingredient, Amarasate™ extract, suppresses food intake and stimulates gastrointestinal peptide hormones in healthy men,” 17(Suppl. 2): 21-34, Abstract No. T2:S… [cited by applicant]
Intelmann et al. (2009) “Three TAS2R Bitter Taste Receptors Mediate the Psychophysical Responses to Bitter Compounds of Hops ( [cited by applicant]
International Search Report and Written Opinion, dated Jul. 5, 2018, for International Application No. PCT/IB2018/052792 (filed Apr. 23, 2018). [cited by applicant]
Ivanova et. (2014) “Solid-state determination of hop bitter acids in beer by UV-MALDI—Orbitrap mass spectrometry,” Food Measure 8: 343-355. [cited by applicant]
Jang et al. (2007) “Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1,” PNAS 104(38), 15069-15074. [cited by applicant]
Janssen et al. (2011) “Bitter taste receptors and (alpha)-gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptying,” PNAS 108(5): 2094-2099. [cited by applicant]
Ji et al. (2014) “Identification of novel compounds for human bitter taste receptors,” Chemical biology & drug design, 84(1): 63-74. [cited by applicant]
Johnston (2016) “Plant drug helps trim diet: study,” available online at https://www.nzherald.co.nz/nz/plant-drug-helps-trim-diet-study/R6DELDQN5HUKO5GSNGDKAI6LEM, 3 pages. [cited by applicant]
Kaji et al. (2009) “Secretory effects of a luminal bitter tastant and expressions of bitter taste receptors, T2Rs, in the human and rat large intestine. American journal of physiology-Gastrointestinal and Liver Physiolo… [cited by applicant]
Kim et al. (2014) “Denatonium induces secretion of glucagon-like peptide-1 through activation of bitter taste receptor pathways,” Diabetologia 57(10): 2117-2125. [cited by applicant]
Konda et al. (2014) “KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes,” PLoS One 9(1): p. e87848. [cited by applicant]
Latorre et al. (2016) “Expression of the Bitter Taste Receptor, T2R38, in Enteroendocrine Cells of the Colonic Mucosa of Overweight/Obese vs. Lean Subjects,” PloS one 11 (2): 16 pages. [cited by applicant]
Le Nevé et al. (2010) “The steroid glycoside Hg-12 from Hoodia gordonii activates the human bitter receptor TAS2R14 and induces CCK release from HuTu-80 cells,” American Journal of Physiology-Gastrointestinal and Liver … [cited by applicant]
Macrae (2016) “The bitter pill that dieters will be very keen to swallow: Substance found in plants can fool the body into believing it is full,” available online at https://www.dailymail.co.uk/news/article-3623002/The-… [cited by applicant]
Meyerhof et al. (2010) “The molecular receptive ranges of human TAS2R bitter taste receptors,” Chemical Senses 35 (2): 157-170. [cited by applicant]
Morimoto-Kobayashi et al. (2015) “Matured Hop Bittering Components Induce Thermogenesis in Brown Adipose Tissue via Sympathetic Nerve Activity,” PLoS One, 10(6): 14 pages. [cited by applicant]
Morimoto-Kobayashi et al. (2016) “Matured hop extract reduces body fat in healthy overweight humans: a randomized double blind, placebo-controlled parallel group study,” Nutrition Journal 15:25: 13 pages. [cited by applicant]
Nolden et al. (2016) “Differential bitterness in capsaicin, piperine, and ethanol associates with polymorphisms in multiple bitter taste receptor genes,” Physiology & Behavior 156: 117-27. [cited by applicant]
Obara et al. (2009) “Isohumulones, the bitter component of beer, improve hyperglycemia and decrease body fat in Japanese subjects with prediabetes,” Clinical Nutrition 28(3): 278-84. [cited by applicant]
Rozengurt et al. (2006) “Colocalization of the (alpha)-subunit of gustducin with PYY and GLP-1 in L cells of human colon,” American Journal of Physiology-Gastrointestinal and Liver Physiology 291: G792-G802. [cited by applicant]
Sternini et al. (2008) “Enteroendocrine cells: a site of ‘taste’ in gastrointestinal chemosensing,” Current Opinion in Endocrinology, Diabetes, and Obesity 15(1): 73-78. [cited by applicant]
Sumiyoshi et al. (2013) “Hop ( [cited by applicant]
University of California—Irvine (2008) “Small Intestine Can Sense And React To Bitter Toxins In Food,” ScienceDaily <www.sciencedaily.com/releases/2008/10/081009185032.htm>. [cited by applicant]
Van Avesaat et al. (2015) “Intraduodenal infusion of a combination of tastants decreases food intake in humans,” Am J Clin Nutr 102(4): 729-735. [cited by applicant]
Wang et al. (2014) “Bitter Taste Mediated Calcium Signaling in Enteroendocrine Cells,” In: Goh J. (eds) The 15th International Conference on Biomedical Engineering. IFMBE Proceedings, vol. 43. Springer, Cham. [cited by applicant]
Wu et al. (2002) “Expression of bitter taste receptors of the T2R family in the gastrointestinal tract and enteroendocrine STC-1 cells,” PNAS 99(4): 2392-2397. [cited by applicant]
Yajima et al. (2004) “Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance,” J Biol Chem 279(32): 33456-33462. [cited by applicant]